Loading…

The History and Future of Probenecid

Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, through...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular toxicology 2012-03, Vol.12 (1), p.1-9
Main Authors: Robbins, Nathan, Koch, Sheryl E., Tranter, Michael, Rubinstein, Jack
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223
cites cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223
container_end_page 9
container_issue 1
container_start_page 1
container_title Cardiovascular toxicology
container_volume 12
creator Robbins, Nathan
Koch, Sheryl E.
Tranter, Michael
Rubinstein, Jack
description Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.
doi_str_mv 10.1007/s12012-011-9145-8
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_926885763</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A711762786</galeid><sourcerecordid>A711762786</sourcerecordid><originalsourceid>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</originalsourceid><addsrcrecordid>eNp1kUFPFTEUhRujAQR-ABsyURNXg_fembbTJSEiJiS6wHXTae_AkPem0M4s-Pf0-VDUSLpo037n3NMcIY4QThBAf8pIgFQDYm2wlXX3SuyhlKYGkub15txArQ3IXfE251sAIlJyR-wSmqZrTbMnPlzdcHUx5jmmh8pNoTpf5iVxFYfqe4o9T-zHcCDeDG6V-fBp3xc_zj9fnV3Ul9--fD07vax9a_RcY4DeaxWAjdMKeiQpAyLr3hBpLY3RrWLP3jTKa2oocHDkGvBDq0q0Zl983PrepXi_cJ7tesyeVys3cVyyNaS6TmrVFPLdP-RtXNJUwlmDXSGgUwV6_xJEykjdaaA_qGu3YjtOQ5yT85vB9lQjakX6p9fJf6iyAq9HHycexnL_lwC3Ap9izokHe5fGtUsPFsFu2rPb9mxpz27as13RHD8FXvo1h9-KX3UVgLZALk_TNafnH73s-ggJPp7f</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2695787026</pqid></control><display><type>article</type><title>The History and Future of Probenecid</title><source>Springer Link</source><creator>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</creator><creatorcontrib>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</creatorcontrib><description>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</description><identifier>ISSN: 1530-7905</identifier><identifier>EISSN: 1559-0259</identifier><identifier>DOI: 10.1007/s12012-011-9145-8</identifier><identifier>PMID: 21938493</identifier><language>eng</language><publisher>New York: Humana Press Inc</publisher><subject>Animals ; Anti-Bacterial Agents - antagonists &amp; inhibitors ; Anti-Bacterial Agents - pharmacokinetics ; Antibiotics ; Biomedical and Life Sciences ; Biomedicine ; Calcium ; Cardiology ; Cidofovir ; Depression ; Depression - drug therapy ; Depression - metabolism ; Emtricitabine ; Excretion ; Fura-2 ; Fura-2 - metabolism ; Gout ; Gout - drug therapy ; Gout - metabolism ; Health services ; Humans ; Hydrochlorothiazide ; Kidney ; Leakage ; Medical colleges ; Neurology ; Penicillin ; Pharmacology/Toxicology ; Physiological aspects ; Probenecid ; Probenecid - chemistry ; Probenecid - pharmacokinetics ; Probenecid - therapeutic use ; Renal function ; Reviews ; Transient receptor potential proteins ; TRPV Cation Channels - physiology ; Uricosuric Agents - chemistry ; Uricosuric Agents - pharmacokinetics ; Uricosuric Agents - therapeutic use</subject><ispartof>Cardiovascular toxicology, 2012-03, Vol.12 (1), p.1-9</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><rights>COPYRIGHT 2012 Springer</rights><rights>Springer Science+Business Media, LLC 2011.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</citedby><cites>FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21938493$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Robbins, Nathan</creatorcontrib><creatorcontrib>Koch, Sheryl E.</creatorcontrib><creatorcontrib>Tranter, Michael</creatorcontrib><creatorcontrib>Rubinstein, Jack</creatorcontrib><title>The History and Future of Probenecid</title><title>Cardiovascular toxicology</title><addtitle>Cardiovasc Toxicol</addtitle><addtitle>Cardiovasc Toxicol</addtitle><description>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - antagonists &amp; inhibitors</subject><subject>Anti-Bacterial Agents - pharmacokinetics</subject><subject>Antibiotics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Calcium</subject><subject>Cardiology</subject><subject>Cidofovir</subject><subject>Depression</subject><subject>Depression - drug therapy</subject><subject>Depression - metabolism</subject><subject>Emtricitabine</subject><subject>Excretion</subject><subject>Fura-2</subject><subject>Fura-2 - metabolism</subject><subject>Gout</subject><subject>Gout - drug therapy</subject><subject>Gout - metabolism</subject><subject>Health services</subject><subject>Humans</subject><subject>Hydrochlorothiazide</subject><subject>Kidney</subject><subject>Leakage</subject><subject>Medical colleges</subject><subject>Neurology</subject><subject>Penicillin</subject><subject>Pharmacology/Toxicology</subject><subject>Physiological aspects</subject><subject>Probenecid</subject><subject>Probenecid - chemistry</subject><subject>Probenecid - pharmacokinetics</subject><subject>Probenecid - therapeutic use</subject><subject>Renal function</subject><subject>Reviews</subject><subject>Transient receptor potential proteins</subject><subject>TRPV Cation Channels - physiology</subject><subject>Uricosuric Agents - chemistry</subject><subject>Uricosuric Agents - pharmacokinetics</subject><subject>Uricosuric Agents - therapeutic use</subject><issn>1530-7905</issn><issn>1559-0259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp1kUFPFTEUhRujAQR-ABsyURNXg_fembbTJSEiJiS6wHXTae_AkPem0M4s-Pf0-VDUSLpo037n3NMcIY4QThBAf8pIgFQDYm2wlXX3SuyhlKYGkub15txArQ3IXfE251sAIlJyR-wSmqZrTbMnPlzdcHUx5jmmh8pNoTpf5iVxFYfqe4o9T-zHcCDeDG6V-fBp3xc_zj9fnV3Ul9--fD07vax9a_RcY4DeaxWAjdMKeiQpAyLr3hBpLY3RrWLP3jTKa2oocHDkGvBDq0q0Zl983PrepXi_cJ7tesyeVys3cVyyNaS6TmrVFPLdP-RtXNJUwlmDXSGgUwV6_xJEykjdaaA_qGu3YjtOQ5yT85vB9lQjakX6p9fJf6iyAq9HHycexnL_lwC3Ap9izokHe5fGtUsPFsFu2rPb9mxpz27as13RHD8FXvo1h9-KX3UVgLZALk_TNafnH73s-ggJPp7f</recordid><startdate>20120301</startdate><enddate>20120301</enddate><creator>Robbins, Nathan</creator><creator>Koch, Sheryl E.</creator><creator>Tranter, Michael</creator><creator>Rubinstein, Jack</creator><general>Humana Press Inc</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>20120301</creationdate><title>The History and Future of Probenecid</title><author>Robbins, Nathan ; Koch, Sheryl E. ; Tranter, Michael ; Rubinstein, Jack</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - antagonists &amp; inhibitors</topic><topic>Anti-Bacterial Agents - pharmacokinetics</topic><topic>Antibiotics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Calcium</topic><topic>Cardiology</topic><topic>Cidofovir</topic><topic>Depression</topic><topic>Depression - drug therapy</topic><topic>Depression - metabolism</topic><topic>Emtricitabine</topic><topic>Excretion</topic><topic>Fura-2</topic><topic>Fura-2 - metabolism</topic><topic>Gout</topic><topic>Gout - drug therapy</topic><topic>Gout - metabolism</topic><topic>Health services</topic><topic>Humans</topic><topic>Hydrochlorothiazide</topic><topic>Kidney</topic><topic>Leakage</topic><topic>Medical colleges</topic><topic>Neurology</topic><topic>Penicillin</topic><topic>Pharmacology/Toxicology</topic><topic>Physiological aspects</topic><topic>Probenecid</topic><topic>Probenecid - chemistry</topic><topic>Probenecid - pharmacokinetics</topic><topic>Probenecid - therapeutic use</topic><topic>Renal function</topic><topic>Reviews</topic><topic>Transient receptor potential proteins</topic><topic>TRPV Cation Channels - physiology</topic><topic>Uricosuric Agents - chemistry</topic><topic>Uricosuric Agents - pharmacokinetics</topic><topic>Uricosuric Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Robbins, Nathan</creatorcontrib><creatorcontrib>Koch, Sheryl E.</creatorcontrib><creatorcontrib>Tranter, Michael</creatorcontrib><creatorcontrib>Rubinstein, Jack</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Cardiovascular toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Robbins, Nathan</au><au>Koch, Sheryl E.</au><au>Tranter, Michael</au><au>Rubinstein, Jack</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The History and Future of Probenecid</atitle><jtitle>Cardiovascular toxicology</jtitle><stitle>Cardiovasc Toxicol</stitle><addtitle>Cardiovasc Toxicol</addtitle><date>2012-03-01</date><risdate>2012</risdate><volume>12</volume><issue>1</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1530-7905</issn><eissn>1559-0259</eissn><abstract>Probenecid was initially developed with the goal of reducing the renal excretion of antibiotics, specifically penicillin. It is still used for its uricosuric properties in the treatment in gout, but its clinical relevance has sharply fallen and is rarely used today for either. Interestingly, throughout the last 60 years, there have been a host of apparently unrelated studies using probenecid in the clinical and basic research arena, including its potential use in the diagnosis and treatment of depression and its use to prevent fura-2 leakage in calcium transient studies. Recently, it has been shown that it is also an agonist of the Transient Receptor Potential Vanilloid 2 channel. Due to its unique action and new findings implicating TRPV channels in physiology and in disease, probenecid may have a new future as a research tool, and perhaps as a clinical agent in the neurology and cardiology fields. We review the history of probenecid in this paper and its potential future uses.</abstract><cop>New York</cop><pub>Humana Press Inc</pub><pmid>21938493</pmid><doi>10.1007/s12012-011-9145-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1530-7905
ispartof Cardiovascular toxicology, 2012-03, Vol.12 (1), p.1-9
issn 1530-7905
1559-0259
language eng
recordid cdi_proquest_miscellaneous_926885763
source Springer Link
subjects Animals
Anti-Bacterial Agents - antagonists & inhibitors
Anti-Bacterial Agents - pharmacokinetics
Antibiotics
Biomedical and Life Sciences
Biomedicine
Calcium
Cardiology
Cidofovir
Depression
Depression - drug therapy
Depression - metabolism
Emtricitabine
Excretion
Fura-2
Fura-2 - metabolism
Gout
Gout - drug therapy
Gout - metabolism
Health services
Humans
Hydrochlorothiazide
Kidney
Leakage
Medical colleges
Neurology
Penicillin
Pharmacology/Toxicology
Physiological aspects
Probenecid
Probenecid - chemistry
Probenecid - pharmacokinetics
Probenecid - therapeutic use
Renal function
Reviews
Transient receptor potential proteins
TRPV Cation Channels - physiology
Uricosuric Agents - chemistry
Uricosuric Agents - pharmacokinetics
Uricosuric Agents - therapeutic use
title The History and Future of Probenecid
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T08%3A12%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20History%20and%20Future%20of%20Probenecid&rft.jtitle=Cardiovascular%20toxicology&rft.au=Robbins,%20Nathan&rft.date=2012-03-01&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1530-7905&rft.eissn=1559-0259&rft_id=info:doi/10.1007/s12012-011-9145-8&rft_dat=%3Cgale_proqu%3EA711762786%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c497t-1d0bc76d0e9a760b1255d11e7b92277599746ecec936c7232deda2a30cf462223%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2695787026&rft_id=info:pmid/21938493&rft_galeid=A711762786&rfr_iscdi=true